Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15911929 | 0.76 | L3MBTL1 (0.38) | L3MBTL1KDM4EPPARGESR1ESR2 | |
| SCHEMBL18210332 | 0.73 | KMT2A (0.34) | KDM4ENPC1RAB9A | |
| SCHEMBL5513086 | 0.73 | KDM4E (0.43) | L3MBTL1KDM4EPPARGESR1ESR2 | |
| SCHEMBL868550 | 0.71 | KDM4E (0.46) | L3MBTL1KDM4EPPARGESR1ESR2 | |
| SCHEMBL4188147 | 0.71 | APLNR (0.37) | APLNRL3MBTL1KDM4EPPARGESR1 | |
| SCHEMBL10229552 | 0.70 | PPARG (0.42) | L3MBTL1KDM4EPPARGESR1ESR2 | |
| SCHEMBL23570309 | 0.70 | KDM4E (0.41) | L3MBTL1KDM4EPPARGESR1ESR2 | |
| SCHEMBL23396073 | 0.70 | KDM4E (0.41) | L3MBTL1KDM4EPPARGESR1ESR2 | |
| SCHEMBL25406477 | 0.69 | APLNR (0.36) | APLNR | |
| SCHEMBL29936489 | 0.68 | NAMPT (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275565-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | APLNR 2887/4885L3MBTL1 4834/4885KDM4E 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.